Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06124846

Determining the Effect of Six Weeks of Cannabis Abstinence on Fronto- Striatal fMRI Markers in Adolescents With Cannabis Use Disorder (ABSCAN)

The goal of this study is to understand the changes in neural correlates of reward in adolescents with and without Cannabis Use Disorder (CUD). The study will collect functional magnetic resonance imaging (fMRI) data at 3 different timepoints with the primary goals of understanding striatal reward-based activation during a Monetary Incentive Delay Task and fronto-striatal fMRI resting-state functional connectivity. The study will also explore self-reported impulsivity. The long-term goal is to advance scientific understanding of neural changes associated with cannabis abstinence and inter-individual variability that cannot be otherwise measured in preexisting observational cohorts such as the Adolescent Brain Cognitive Development Study.

This parallel intervention study will collect fMRI data in adolescents ages 15-18 years old with and without CUD at three different timepoints over the course of their intervention. Utilizing a validated paradigm, adolescents with CUD will be randomized to 6-weeks of either incentivized, biochemically verified abstinence via contingency management or monitoring with no required abstinence. Age- and sex-matched adolescents with no lifetime history of cannabis use will also complete the protocol. Participants will complete 9 study visits (3 with fMRI scans) involving urinalysis to confirm cannabis self-report and measures of impulsivity. Participants may additionally and optionally (1) complete daily remote self-report assessments of cannabis use, impulsivity, and mood throughout the 6-week treatment period, and (2) continue participation for an additional 6-week monitoring period after the treatment period, during which they complete daily remote self-report assessments of cannabis use, impulsivity, and mood.

Recruiting

Interested in participating?

Request Info

Key information

Age range

15 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Minnesota

Minneapolis, Minnesota, 55414, United States

Location status: Recruiting

Location contact

Chris Madden

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female adolescents between the ages of 15 and 18 (inclusive).
  • Have a parent or legal guardian who is able and willing to provide written informed consent.
  • Competent and willing to provide written informed assent (participants <18) or consent (participants=18).
  • Native English speaker.
  • Have a parent or legal guardian who is fluent in English.
  • Able to commit to 9 study visits in approximately 60 days (6 weeks).
  • Able to safely participate in the protocol and appropriate for outpatient level of care, in the opinion of the PI.
  • No active psychosis or current use of antipsychotic medications.
  • Participants taking psychotropic medications will be included if the medications have been stable for 6 weeks and are expected to remain stable for the duration of their study participation (i.e., through the third MRI).
  • For CB-Abst (n=24) and CB-Mon (n=20) groups: at least 5 days of use per week on average in the past two months and meet DSM-V cannabis use disorder (CUD; at least Mild) criteria. Cannabis use reported within seven days of baseline visit. Positive qualitative urine toxicology test at baseline for THC. No immediate plan to discontinue cannabis use.
  • For Con (n=20): no lifetime history of cannabis use. Negative qualitative urine toxicology test at baseline for THC. No immediate plans to begin cannabis use.
  • For optional components (A: daily remote assessments during and/or (B) after treatment period): access to a personal device (e.g., smartphone or computer) on which to complete daily remote assessments.

Exclusion criteria

  • Past twelve-month history of substance use disorders (except for Cannabis Use Disorder in CB-Abst and CB-Mon), assessed via semi-structured psychodiagnostics interview at baseline.
  • Contraindications for MRI (ascertained via participant and parent report), including but not limited to:
  • Metal implants such as surgical clips or pacemakers, or history of working with metal, unless the possibility of a metal fragment can be ruled out by recent orbital scans.
  • Prior head trauma with neurological sequelae.
  • Claustrophobia.
  • Weight incompatible with MRI safety.
  • Pregnancy.
  • Previous or current diagnosis of psychosis, cognitive disability, or bipolar disorder.
  • Active suicidality.
  • Taking a psychotropic medication that has not reached stability criterion (same medication type and dose for 6 weeks with no planned changes over the study period).
  • Any other medical or psychiatric condition deemed serious or contraindicated for any study procedures by Dr. Tervo-Clemmens.

Treatment and study plan

CB-Abst

Behavioral

incentivized, biochemically verified abstinence via contingency management

CB-Mon

Behavioral

monitoring with no required abstinence

Primary outcomes

  1. Brain activation during Monetary Incentive Delay Task (reward processing)

    Time frame: baseline, week3, week 6

    A neural measure of reward activation will be defined as the difference between reward positive vs negative feedback in the standardized Harvard Oxford Striatal atlas during the MID Task.

  2. Brain connectivity during resting-state functional neuroimaging protocol

    Time frame: baseline, week 3, week 6

    A neural measure of reward-circuitry connectivity will be defined as the correlation values between standardized striatal and salience and orbitofrontal and salience cortical networks

Secondary outcomes

  1. Self-reported Impulsivity via UPPS-P scale

    Time frame: baseline, weeks 1,2,3,4,5 and 6

    Self-reported impulsivity will be defined by Total and Premeditation (lack of), Urgency, Sensation Seeking, Perseverance (lack of) scores

Study contacts

Contact information is provided by the study sponsor or research team.

Venessa Fuentes

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

University of Minnesota

Other

Registry information

Important dates

Study start
2024
Primary completion
2028
Study completion
2028
First posted
Nov 9, 2023
Registry last updated
Apr 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.